Ann: GBM Agile Update, page-104

Some think 9 trial activities is nothing, Some think it is something…

And so do actual scientists like Matt Dunn, St Jude’s, Dana-Farber, the global coalition for adaptive research, Sloan Kettering

Someone once said Kazia could never get a trial up as each cost around 20 million - that’s EACH! And yet here we are.

So what a bargain we have had to progress 9 for 22 million through a whole year!!



we know that we are now in stage 1 for GBM Agile and maybe 150 patients and these much larger numbers are reporting data next year - if the data confirms our own phase 2 we may submit an application to FDA imho…

i get that even after all these years later some still wrestle with this - it’s too risky and by the time it’s de-risked returns are commensurately in alignment with that.

all I can say is we all get the reward we deserve!